Privacy settings may have prevented some items from showing.
Please update your search criteria and try again
It’s an exciting time for new TB vaccine development! Several vaccine candidates are in late stage product development, with Phase III trial data available as early as 2024 and potential licensure and use in some countries in the near future. However, none of the candidates are expected to be a ‘silver bullet’ and there are differences in terms of trial design, primary endpoint, target population, and product attributes. Without a known correlate of protection, the effect of HIV status, infection status, age and geography on vaccine efficacy must be determined for each vaccine. We also need to ensure that the early pipeline remains robust in terms of new antigenic targets and platforms, and that new tools are developed to effectively evaluate their potential efficacy.
This webinar will bring together experts to discuss the status of TB vaccine development across the value chain, from articulation of the public health and economic need for new TB vaccines, through the status and strategies for product development, to the considerations for approval, policy recommendation and use.
Register here: https://who.zoom.us/webinar/register/WN_B1qi05_KT9Om_EaGRhqGBg#/registration
Dear Colleagues,
Through the Global Vaccine and Immunization Research Forum (GVIRF) collaboration, World Health Organization,NIAID, and the Bill & Melinda Gates Foundation are organizing a webinar; information, including a link to register may be found below, or in the attached flyer.
Webinar Title: Vaccines as Tools to Prevent Antimicrobial Resistance: advances, challenges and future development
When: June 23 2022, 3-6 pm (CEST), 9-12 am (EDT), 6-9 am (PDT)
Registration (no-cost): https://who.zoom.us/webinar/register/WN_Iudu_2LtRIqv6hA6IkCkBQ
Purpose: This webinar will explore the mechanisms, evidence and value of vaccines in preventing AMR. A panel of experts will discuss what are the challenges to ensure that vaccines to prevent AMR are developed and widely used.
Since World Pneumonia Day was established over a decade ago, global implementation of vaccines to prevent pneumonia has progressed despite disruptions caused by the COVID-19 pandemic. Delivery of pneumococcal conjugate vaccines (PCV) remains a high priority for countries as a critical tool for reducing child mortality and meeting SDG goals. Investments in scaling up and measuring the impact of PCV have helped boost the pandemic response in some countries, and countries have progressed with PCV rollouts while also introducing COVID-19 vaccines. The pandemic has progressed the successful use of mRNA vaccines to the forefront of global health and further development and attention to this platform may be beneficial for the future of PCV in low-resource settings.
Panelists:
- Arup Deb Roy, MD, Project Director, John Snow, Inc.
- Keith Klugman, MD, PhD, Director, Pneumonia, Bill & Melinda Gates Foundation
- Lee Hampton, MD, Pediatrician and Medical Epidemiologist, Gavi, the Vaccine Alliance
- Wangeci Kagucia, PhD, Research Fellow, KEMRI-Wellcome Trust Research Programme
Register here: https://jh.zoom.us/webinar/register/WN_MstuzjmrTL-YsIpfTOVJbA
Join Dr. Peter Hotez for a 60-minute webinar hosted by the International Vaccine Access Center to discuss topics ranging from vaccine diplomacy, the antivaccine movement, safety surveillance, and a new COVID vaccine.
Register here: https://jh.zoom.us/webinar/register/WN_nAC77r7vSjKKHoc4rTwN7A?timezone_id=UTC
Webinar series: WHO Costing, Budgeting, Financing and Delivery of COVID-19 Vaccines
The WHO’s Department of Immunization, Vaccines and Biologicals (IVB) and WHO Health Emergency programme (WHE) are partnering with Project ECHO of the University of New Mexico (UNM), UNICEF, and TechNet-21 to host a series of 15 sessions that align with countries’ immediate and medium-term needs.
Final session: Global Status Update: A year in reflection and a year ahead
Registration link: https://echo.zoom.us/webinar/register/WN_-laAatzPS1SeSxvJmF-PNg
Interpretation into French and Spanish will be available
Trusted voices – who, why and how to communicate about COVID-19 vaccines
When: Thursday 8 July, 2021
14.00 - 15.30 Geneva,
17.30 - 19.00 Delhi,
08.00 - 09.30 New York
WHO, UNICEF and Religions for Peace are pleased to invite you to Webinar 3 of the joint series. During this webinar we will discuss why trusted voices are important during crises; how to address or respond to current questions about COVID-19 vaccines and the role of faith leaders in supporting vaccine uptake in their communities.
Panelists:
Melinda Frost (MA, MPH) Translate Science Team Lead, COVID-19 Response, World Health Organization,
Geneva Leilia Dore (MPH) Technical Consultant for Risk Communications and Community Engagement, COVID-19 Vaccines, World Health Organization, Geneva
Q&A Participants will be able to submit questions during the webinar by using Zoom's "Q&A" feature. You may also submit them in advance by sending them to Sarah Hess: [email protected]
Register for the Webinar here: https://who-e.zoom.us/webinar/register/WN_yOv_HZMMQbuVXQJlshW4FQ
A live webinar organised by CDDEP, in collaboration with the WHO
How can vaccines address the problem with AMR?
SPEAKERS:
Dr. Hanan Balkhy,
Assistant-Director General for AMR, WHO
Deepali Patel MPH, Acting Head, Policy, Gavi
Dr. Padmini Srikantiah,
Senior Program Officer, AMR Strategy Lead
Bill & Melinda Gates Foundation
Dr. Mateusz Hasso-Agopsowicz,
Technical Officer, WHO
Dr. Joseph Lewnard,
Assistant Professor, UC Berkeley
With an introduction from Dr. Ramanan Laxminarayan, Director at CDDEP.
This is part of a webinar series celebrating 10 years of CDDEP, highlighting research on Antimicrobial Resistance, Vaccines, and COVID-19
Note: You can also follow this webinar LIVE on Facebook at: https://m.facebook.com/cddep/live
(this does not require a Facebook account)
Register here https://us02web.zoom.us/webinar/register/WN_68qd-db0S1O4JUi4S6_w7A?timezone_id=UTC
The International Vaccine Access Center (IVAC) on March 23, 2021 at 11:00am ET will host a 60-minute webinar SARS-CoV-2 Variants and the Safety of COVID-19 Vaccines in the U.S.
Description: Join us for a special webinar presentation about COVID-19 vaccine safety in the U.S. and the potential impact new variants will have on vaccine effectiveness. The speed and coordination of the response against COVID-19 and development of vaccines is unprecedented, but there are still unknowns and issues to overcome. In a moderated conversation, hear from experts on safety monitoring, reporting, and challenges with emerging variants.
Register here https://jh.zoom.us/webinar/register/WN_8WjhsDjvTwm09BlhtvnPcg?timezone_id=UTC
In collaboration with Common Thread, LNCT captured the vaccination journeys of two families within a H’mong community in Yên Bái Province, Vietnam. Their stories, captured in their own words, show how community engagement strategies can be used effectively to create empathy and build demand for vaccines among vulnerable groups. LNCT and Common Thread are pleased to share these case studies with you at an upcoming launch on Thursday, March 18th. During this video launch webinar, Common Thread will walk participants through the two journeys, reflect on the strategies used in the community, and explore how these materials can be used to build skills to generate demand for vaccines amongst ethnic minorities in other contexts.
Date: March 18, 2021
Time: 6:00-7:15 am EDT / 11:00 am-12:15 pm Abuja / 2:00-3:15 pm Tbilisi / 3:30-4:45 pm New Delhi
Details: This session will be hosted in English, but simultaneous interpretation will be provided live on Zoom in French, Portuguese, and Russian, as needed. If you require interpretation, please confirm which language when you register. We recommend you register by March 12th to ensure interpretation can be arranged in advance.
Register here https://r4d-org.zoom.us/webinar/register/WN_MzVGrueMTMCYbTphpjUZsg
All eyes are on the global rollout of COVID-19 vaccines. Over the coming months, vaccine manufacturers, regulatory authorities, logistics experts and healthcare practitioners alike are facing the daunting challenge of delivering billions of vaccine doses around the world and ensuring that every dose remains safe and effective.
Achieving the public confidence and broad uptake of COVID-19 vaccines needed to reach population immunity and curb the virus’s spread will require an unprecedented effort among health workers, scientists and stakeholders at every step of the supply chain.
During development and delivery, how will we guarantee that quality is maintained for authorized and approved vaccines? How will we build and strengthen health system capacity to implement quality vaccination services, especially in LMICs facing insufficient health system resources and inadequate vaccine supply? Finding the solutions to these questions will be a defining challenge of 2021 and a key hurdle to getting vaccines to the people who need them the most. This virtual event will convene two expert panels moderated by Zain Verjee (former CNN International Anchor) with participation from Soumya Swaminathan (WHO), Bruce Gellin (Sabin Vaccine Institute), Ron Piervincenzi (USP) and others from organizations central to the COVID-19 response who will dive into existing concerns and explore novel, future solutions that will bolster public trust in the vaccine effort and help ensure an equitable rollout.
Please submit any questions you may have for the event Q&A in advance to [email protected].
Register here https://zoom.us/webinar/register/WN_S69BcKzhRDy8ll1I1SRuxw?timezone_id=UTC
Given the need for an ultra-cold chain (UCC) for an initial leading COVID-19 vaccine candidate, Project Last Mile conducted an analysis on the availability of liquid CO2 (LCO2) within the Coca-Cola value chain in 47 countries in Africa to assist in meeting potential dry ice needs to support ultra-cold chain vaccine distribution. This was then expanded to include COVAX countries in Latin America and the Pacific Islands. Ultimately, Project Last Mile completed a rapid assessment examining the feasibility of procuring LCO2 in 70 countries from Coca-Cola partners and suppliers across the three regions.
The upcoming webinar: Findings on the operational feasibility of maintaining ultra-cold temperatures to distribute COVID-19 vaccines – the availability of dry ice within the Coca-Cola value chain in 70 countries will be held on Thursday, March 11, 2021, at 8:00 am PST (UTC-8 hours). At the following link, you can look up the webinar timing in your local time zone: https://tinyurl.com/38jco5ah.
This webinar will share the culmination of this study. The aim is to contribute significant insights into determining the operational feasibility of maintaining ultra-cold temperatures to distribute COVID-19 vaccines. The findings can also inform where COVID-19 vaccines requiring ultra-cold chain may not be feasible or will require another LCO2 procurement approach.
Project Last Mile (PLM) is an innovative public-private partnership launched in 2010 between The Coca-Cola Company, The Coca-Cola Foundation, United States Agency for International Development (USAID), President’s Emergency Plan for AIDS Relief (PEPFAR), The Global Fund, and Bill & Melinda Gates Foundation to draw private-sector lessons from across the Coca-Cola value chain to benefit health systems strengthening in Africa.
The webinar will be led by Jonathan Halse, who undertook the analysis for Project Last Mile. Jonathan currently leads Supply Chain Redesign Projects across multiple countries in Africa with Project Last Mile. Jonathan has worked for many leading FMCG leadership brands, including Coca-Cola, Mars, and Pepsi, where he held numerous leadership positions in operations and was deeply involved in capability building in many diverse markets across Africa, Asia, and the Middle East. The webinar will be opened by Alexandra Scott, Director of Program Delivery for Project Last Mile.
Time will be dedicated to answering questions from national and sub-national focal points.
If you haven’t yet registered for this event, you can do so here:
https://who.zoom.us/webinar/register/WN_NQgjfCWORLGd4h-ge2MurA
The session will build upon the findings in:
https://www.technet-21.org/en/?option=com_easydiscuss&view=post&id=6257&Itemid=1747
We look forward to welcoming you on the call. Please feel free to ask follow-up questions by replying to this post:
As countries around the world respond to the COVID-19 pandemic, already strained health supply chains are being tested. Empower School of Health and The Pharmaceutical Society of Sierra Leone (PSSL) are hosting a webinar on Strengthening Immunization-Supply chain management and preparing for COVID-19 Vaccines.
The key objectives of this webinar are:
1. Discussing key considerations for a new COVID-19 vaccine introduction in health systems and the associated supply chain requirements and
2. How they might influence the future of supply chains in a post-COVID-19 world.
Register here to join us: http://bit.ly/empower_PSSL_immunization
DATE: 18 February 2021
TIME: 10:00 am-11.30 am Greenwich Mean Time
The Visibility for Vaccines (ViVa) platform is a stock visibility dashboard that visualizes the pipeline of current stocks, vaccine orders as well as forecasts. It enables country governments to better identify and prevent potential vaccine stock outs or overstocks before they occur. The platform was developed by UNICEF, with funding from the UPS Foundation, and first introduced in 2016. ViVa currently has over 350 registered users in 37 countries.
This new course trains users on the functionalities of the ViVa platform, how to effectively analyze and interpret ViVa’s dashboards and data, as well as on how to integrate this analysis into routine business processes in countries. By adopting this comprehensive approach, the training aims to both strengthen Viva user competencies as well as promote a more data-based approach to vaccine supply decision-making.
The main target audience for this course are national government EPI staff. UNICEF country and regional staff, as well as other in-country vaccine partners, will also benefit from this course.
The training is availble on the Agora training website and is available in French and English.
You can access the course through the following links:
English: https://agora.unicef.org/course/view.php?id=25034
French: https://agora.unicef.org/course/view.php?id=25803
Dear VPPN Members:
We are pleased to invite you to a Knowledge Sharing Session on:
Learning from sub-regional experiences in cross-country collaboration
in the procurement of medicines and vaccines
Key learning objectives:
- Sharing research findings from WHO EURO report on Cross-Country Collaborations to improve access to medicines and vaccines
- Understanding benefits of cross-country collaboration for vaccine procurement
- Providing lessons learned about cross-country collaboration from sub-regional examples including the ‘Baltic Procurement Initiative’ and BeNeLuxa Initiative
Date & Time:
Thursday, 29 October 2020, 2020 09:00-10:00AM Copenhagen time (CET)
Presenters:
- Ms Tifenn Humbert, Technical Officer, Access to medicines and health products Division of Country Health Policies and Systems, WHO, Copenhagen, Denmark
- Dr Oleg Benes, Technical Officer, Vaccine-preventable Diseases and Immunization at WHO/Europe
- Ms Eveli Bauer, Chief specialist, Pharmaceuticals and Medical Devices Department, Estonian Health Insurance Fund
- Francis Arickx, Advisor general, Head of Directorate, Directorate Pharmaceutical Policy, Health Care Department, National Institute for Health and Disability Insurance (RIZIV INAMI), Brussels, BE, Representative of BeNeLuxa Initiative
- Sub-Regional speaker – to be confirmed
Moderators:
- Andrea Papan, VPPN, Community of Practice Manager, UNICEF
- Loïc Sanchez, Supply Officer (Immunization), Supply Division, UNICEF
Additional Resources:
- Cross-country collaborations to improve access to medicines and vaccines in the WHO European Region (2020)
- 4th PPRI Conference: Medicines access challenge – The value of pricing and reimbursement policies, Abstract Poster Book
- ASEAN Vaccine Security and Self-Reliance (AVSSR) Initiatives: A Healthy ASEAN Community through Access of Assured Quality Vaccines
PLEASE NOTE: Registration is compulsory to participate in this webinar:
Register in advance for this webinar:
https://unicef.zoom.us/webinar/register/WN_cUuhWCMGQaaZTBG-v3IHFw
Or an H.323/SIP room system:
H.323:
162.255.37.11 (US West)
162.255.36.11 (US East)
221.122.88.195 (China)
115.114.131.7 (India Mumbai)
115.114.115.7 (India Hyderabad)
213.19.144.110 (Amsterdam Netherlands)
213.244.140.110 (Germany)
103.122.166.55 (Australia)
209.9.211.110 (Hong Kong SAR)
64.211.144.160 (Brazil)
69.174.57.160 (Canada)
207.226.132.110 (Japan)
Meeting ID: 956 9635 6376
Passcode: 119398
SIP: [email protected]
Passcode: 119398
After registering, you will receive a confirmation email containing information about joining the webinar.
We look forward to your participation!
Kind regards,
Andrea
How much more are we willing to pay for a vaccine that can be used outside of the cold chain? Are the trade-offs of paying more for a CTC-qualified vaccine worthwhile? How and when is CTC a good investment for national immunization programs? This presentation will address these questions, presenting the key economic arguments in favour of CTC implementation from a country perspective.
Presenters: Anna-Lea Kahn (WHO); Mercy Mvundura (PATH)
Registration: https://who.zoom.us/meeting/register/tJYldeutrjosEtxl1XHL3q2PGmzFoy4klUcd
Measles and rubella vaccines are safe and effective, however, achieving equitable coverage, particularly for the second dose of measles containing vaccine (MCV2) is well below the 95% target of immunized children. Consequently, there were over 140,000 deaths globally, in 2018. Novel and improved vaccine delivery platforms such as microarray patches (MAPs) are needed to address the increasing challenge of achieving and sustaining effective vaccination of MRVs, to achieve the eradication of measles and rubella, a goal set by the WHO and partners. MAPs offer competitive advantages over needle and syringe (NS) vaccine delivery. They have a potential to be more thermostable and freeze resistant, do not require reconstitution resulting in an improved safety profile, they are easier to use, do not contain sharps, and are more acceptable by caregivers and vaccinees.
Measles and rubella MAPs (MR-MAPs) will soon enter phase one clinical trials and although early in development, critical actions are needed to prepare the pathway for late stage product development and mitigate against delays in scale up. The lack of a clear demand forecast for MR-MAP has been identified as significant bottleneck in the investment of this urgently needed innovative vaccine. In order to address this, the WHO is working with public health stakeholders at the country level to assess how MR-MAPs will be used, the critical product attributes that are required for use to achieve impact, and the potential demand for such products.
Presenter: Mateusz Hasso-Agopsowicz (WHO)
Registration link: https://who.zoom.us/meeting/register/tJYldeutrjosEtxl1XHL3q2PGmzFoy4klUcd
The COVID-19 pandemic has disrupted billions of lives and threatens to reserve decades of development gains. The secondary effects of the pandemic could result in more lives lost from vaccine preventable diseases than from COVID-19. The best way to mitigate the primary and secondary impacts of COVID-19 is to safeguard immunization services and strong health systems and ensure equitable access to future COVID-19 vaccines.
The objective of this side event is to galvanize governments and humanitarian actors to safeguard interuppted immunization campaigns, outline key infrastructure that needs to be in place by the time a COVID-19 vaccine is developed, and highlight the need for global coordination to implement equitable access to a COVID-19 vaccine. It also seeks to bring visibility to the COVAX Facility as the only current viable and pragmatic way to plan for equitable access and distribution of the future COVID-19 vaccine for all countries, with a focus on the most vulnerable.
https://ungaguide.com/event/vaccines-for-the-many-or-only-the-few-immunizations-and-covid-19/
Greetings from IIHMR UNIVERSITY, JAIPUR , INDIA
I take immense pleasure to share with you that School of Pharmaceutical Management; The IIHMR University is organizing a 05 days International training programme on “Logistics Management of Vaccines with special focus on Strengthening Cold chain ” during April 20-24,2020 at The IIHMR University, Jaipur, India .
The program is designed primarily with a focus to assist the countries/national health system programs to address the challenges in vaccine management thus ensuring access to quality vaccines in the immunization program. The program contents are as below
PROGRAM CONTENTS: -
Introduction to immunization basics and Universal Immunization Program (UIP)
Procurement of vaccines
Cold chain management
Key elements of cold chain system
Cold chain Equipment’s and their maintenance
Monitoring the cold chain temperature
Vaccines Management
Demand estimation
Indenting
Stock Management
Storage & Distribution
Supportive supervision
Reporting/Documentation & MIS
AEFI and Immunization Waste Management
eVIN- Effectively managing vaccine logistics
Social mobilization, advocacy and communication for EPI
Field visit to cold chain point
Hands on training on temperature monitoring devices
PROGRAMME FEE
• Foreign Nationals: USD 700 per participant plus 18% GST
• Indian Nationals: Rs 37,500 per participant plus 18% GST
The fees cover tuition fees, training material, stay in air-conditioning room (twin-sharing basis), breakfast, lunch, dinner, tea/coffee during the program and pick-up and drop from Jaipur airport/railway station/bus stand. Welcome dinner and short-trip to historical and cultural importance places in Jaipur would be offered by the University in honor of the participants. Participants would be encouraged to use library facilities. Around the clock internet facility (Wi-Fi) is available for the participants. The travel tickets from the country of origin to Jaipur and vice versa are to be borne by the participant/sponsoring agency.
DISCOUNTS ON THE FEE
Early Bird Discount: Nominations received with payments on/before 4-weeks (23rd March 2020) will be entitled to an early bird discount of 10%.
Group Discount: Any organization sponsoring four or more participants to the program will be entitled for a discount of 20% on the total fee payable provided that at least four participants attend the program.
Maximum Discount: Organization can avail themselves of both the discount subject to maximum discount of 20%.
I am sure that you will find it useful for the organization/national health system program.
I would be grateful, if you could participate/ nominate interested candidates in the training program.
You may forward to concerned department also
Kindly send the filled and scanned nomination form (attached) to the program coordinator at [email protected]
Looking forward for your kind cooperation and support to make the program success.
A word of response would be appreciated.
Link for the brochure
https://www.iihmr.edu.in/files/training/brochure/170/logistics-management-of-vaccines.pdf
Regards
Dr.Saurabh kumar Banerjee
M.Pharm, Ph.D., MBA
Associate Professor and Program Coordinator
The IIHMR University,
1 Prabhu Dayal Marg, Near Sanganer Airport
Jaipur (Pin-302029), Rajasthan, INDIA
Office: +91 141 3924700, Ext: 789,
Fax: +91 141 3924738,
Mobile - +91-8890398067
Email: [email protected]